Clinical
Strong Pipeline Targeting 4 Cancer Indications With High Unmet Medical Need (Ny tekst her)
Pipeline
Cbio’s novoleucel TIL product licensed from Herlev Hospital has been tested clinically in more than 100 patients spanning 12 different solid tumor indications in 9 different clinical studies. Here, novoleucel has proven to be safe and tolerable with overall response rates up to 46% and complete remission in up to 13% in a late-stage cancer patient population.
It is currently being investigated in a phase III trial in metastatic melanoma in a large investigator-led clinical study. Cbio aims to initiate a company-sponsored pivotal clinical trial validating novoleucel in the following four cancer indications: cervical cancer, lung cancer, metastatic melanoma, and head & neck cancer with the goal to obtain a conditional marketing authorization.
In addition, Cbio is collaborating with Odense University Hospital in Denmark, to evaluate the feasibility and develop novoleucel for an additional four cancer indications: colorectal, ovarian, kidney, and pancreatic cancer.
Novoleucel 1st generation manufacturing protocol (Herlev)
Novoleucel next generation manufacturing protocol (Cbio proprietary)
Investigator-led studies based on first-generation TIL protocol
TIL product: CB-104
*Head & Neck, NSCLC, Cervical, Colorectal, Cholangiocarcinoma, Leiomyosarcoma, Uveal Melanoma, Adreno-corticoid Carcinoma, Thyroid Cancer
Cbio-company sponsored confirmatory studies based on next-gen protocol
TIL product: CB-105
Pre-clinical study with Odense University Hospital
TIL product: CB-105
